30 Medical Writing CROs

What is medical writing and when do you need it?

Medical writing is the discipline of turning clinical data and a scientific argument into the regulated documents a trial and a submission run on. It is not copywriting and it is not academic publishing. A medical writer takes a statistical output, a study design, or a safety dataset and produces a document that says exactly what the data support, in the structure a regulator expects, with every claim traceable back to a source. The core deliverables are clinical-trial documents (the protocol, the investigator brochure, the informed consent form, the clinical study report) and the clinical sections of a marketing application.

You first need a medical writer before your trial starts, because the protocol and the IB are written documents before they are anything else, and a sloppy protocol generates amendments that cost real money and time. You need one again at the back end of every study, when the database locks and the clinical study report (the ICH E3 document that formally reports the trial) has to be drafted, usually against a hard timeline tied to your next milestone. And you need a different gear entirely at submission, when the Module 2 summaries (the Clinical Overview and the Clinical Summary) and the Module 5 study reports have to tell one coherent story across an entire program for an NDA, BLA, or MAA.

Most biotechs do not staff this in-house, and for good reason. The workload is spiky: nothing for months, then three documents due in the same six weeks. Regulatory medical writing also rewards people who have done it many times, who know how a reviewer reads a benefit-risk section and where programs get tripped up on consistency between the CSR, the summaries, and the label. That combination, intermittent demand plus deep specialist judgment, is exactly the kind of work sponsors outsource to a CRO rather than hire for.

What does a medical writing CRO actually do?

A medical writing CRO covers two related but distinct families of work, and it helps to know which one you are buying. Regulatory medical writing produces the documents that go to an agency or govern a trial: protocols and amendments, investigator brochures, informed consent forms, clinical study reports, the Common Technical Document clinical modules (Clinical Overview, Clinical Summary, the integrated summaries of safety and efficacy), patient narratives, briefing documents for FDA meetings, and pediatric or orphan-designation submissions. Scientific and medical-affairs writing produces manuscripts, abstracts, posters, congress materials, and plain-language summaries. The two often live in separate teams, so confirm the vendor is strong in the family you actually need.

The day-to-day is more than drafting. A good writer manages the source documents, runs the comment-and-reconciliation cycles across biostatistics, clinical, regulatory, and safety reviewers, keeps version control clean so the document that gets filed is the document that was approved, and enforces consistency so the numbers in the CSR match the tables, the summaries, and eventually the label. Increasingly that work runs in a structured-content or component-authoring environment and follows data standards, so the writer is also making sure the document plays nicely with CDISC datasets and the agency's electronic submission requirements rather than being remediated at the end.

• Clinical-trial documents: protocols and amendments, investigator brochures (IBs), informed consent forms (ICFs), and clinical study reports (CSRs) to ICH E3
• Submission authoring: CTD Module 2 summaries (Clinical Overview, Clinical Summary), integrated summaries of safety and efficacy (ISS/ISE), and Module 5 study reports
• Safety and regulatory documents: patient narratives, DSURs, aggregate safety reports, FDA and EMA briefing documents, and responses to agency questions
• Scientific and medical-affairs writing: manuscripts, abstracts, posters, congress decks, and plain-language summaries (separate from regulatory writing)
• Process work: source-document management, comment reconciliation across functions, version control, and quality-control review against the source

How to choose a medical writing CRO?

Writing samples are cheap to promise and expensive to verify, so push past the pitch. Ask to see a redacted CSR or a Module 2 summary the team actually authored, not a template, and have your own clinical or regulatory lead read it. The thing you are really buying is judgment: whether the writer can hold a benefit-risk argument together across a dossier, write a tight safety narrative, and catch the inconsistency between a table and the text before a reviewer does. The cheapest quote rarely wins here, because a weak document on a submission timeline is the kind of error that delays a filing.

Two practical fit questions decide most engagements. First, document and submission-type match: a team that is excellent at protocols may have never written an integrated summary of safety, and a manuscript shop is not a regulatory writing shop. Second, therapeutic-area and modality fluency, because a writer who knows your indication and whether you are working a small molecule, an antibody, an ADC, or a cell or gene therapy will need far less hand-holding on the science. Then look at the operational realities below before you sign.

• Quality and GxP status: GCP-aligned processes, ICH E3 and E6 fluency, a documented QC and source-verification step, and a clean regulatory track record
• Capacity and lead time: real availability against your timeline, named writers rather than a logo, and an honest read on CSR and submission turnaround given your data-lock date
• Modality and indication fit: prior work in your therapeutic area and your modality, so the writer understands the science without a long ramp
• Region and regulatory track record: experience with the agencies you are filing to (FDA, EMA, PMDA, NMPA) and the document conventions each expects
• Data quality and standards: CDISC-aware authoring, eCTD-ready output, consistency control across CSR, summaries and label, and structured or component authoring where it matters
• IP and confidentiality: clear ownership of the documents you pay for, tight CDA terms, and disciplined handling of unblinded and pre-submission data